AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease [Yahoo! Finance]
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.